0 Kommentare
0 Anteile
109 Ansichten
0 Vorschau
Search
Entdecken Sie neue Leute, neue Verbindungen zu schaffen und neue Freundschaften
-
Please log in to like, share and comment!
-
Residual DNA Testing Market Analysis Shows Strong Growth in Cell and Gene TherapyMarket Overview The Residual DNA Testing Market is witnessing steady growth, driven by the rapid expansion of biopharmaceutical manufacturing, increasing demand for biologics and vaccines, and stringent regulatory requirements for product safety and quality assurance. Residual DNA testing plays a critical role in ensuring that biopharmaceutical products are free from harmful host-cell DNA...0 Kommentare 0 Anteile 167 Ansichten 0 Vorschau
-
[ Latest Report ] Cell And Gene Therapy Clinical Trial Market 2025 Industry Growth Production Analysis with top playersCell And Gene Therapy Clinical Trial Market Summary “The global Cell And Gene Therapy Clinical Trial Market is expected to reach to USD 14.9 billion by 2032, growing at a CAGR of 13.6% during 2025 to 2032” The TrendBridge Insights Research report, “Global Cell And Gene Therapy Clinical Trial Market Report 2025 – Future Opportunities, Latest Trends, In-depth...0 Kommentare 0 Anteile 962 Ansichten 0 Vorschau
-
Global Biopharmaceutical and Bio-CDMO Market Growing at 14.2% CAGR Through 2032According to a new report from Intel Market Research, the global Biopharmaceutical and Bio-CDMO market was valued at USD 25.71 billion in 2024 and is projected to grow from USD 28.95 billion in 2025 to USD 63.88 billion by 2032, exhibiting a robust CAGR of 14.2% during the forecast period (2025–2032). This growth is driven by increasing demand for biologics and biosimilars due to their...0 Kommentare 0 Anteile 11 Ansichten 0 Vorschau
-
United States Sterile Fill-Finish for Cell and Gene Therapies Market Growing at 8.9%According to a new report from Intel Market Research, the United States Sterile Fill-Finish for Cell and Gene Therapies Market was valued at USD 0.54 billion in 2025 and is projected to reach USD 1.04 billion by 2034, growing at a robust CAGR of 8.9% during the forecast period (2025–2034). This expansion is driven by accelerating investments in cell‑and‑gene therapy pipelines, supportive...0 Kommentare 0 Anteile 327 Ansichten 0 Vorschau